Cord Blood News Volume 6.25 | Jul 3 2014

Engraftment Kinetics and Graft Failure after Single Umbilical Cord Blood Transplantation Using Myeloablative Conditioning Regimen
Investigators analyzed engraftment kinetics and outcomes of 1268 patients (73% children) with acute leukemia (64% acute lymphoblastic leukemia, 36% acute myeloid leukemia) in remission who received single-unit umbilical cord blood transplantation after myeloablative conditioning regimen. [Haematologica]
Abstract | Full Article

IL-4 and IL-13 Differentially Regulate TLR-Induced Eosinophil-Basophil Differentiation of Cord Blood CD34⁺ Progenitor Cells
Cord blood CD34⁺ cells from healthy donors were cultured with IL-4 or IL-13 (in combination with lipopolysaccharide) and assessed for eosinophil-basophil differentiation using methylcellulose cultures and flow cytometry for related intracellular signalling pathways. [PLoS One] Full Article

Cord Blood Transplantation Is Associated with Rapid B-Cell Neogenesis Compared with BM Transplantation
The authors retrospectively analyzed T-cell receptor excision circles as well as signal and coding joint kappa-deleting recombination excision circles as markers of newly produced lymphocytes in 133 patients. Compared with BM and peripheral blood, their data suggested that cord blood provided rapid B-cell recovery. [Bone Marrow Transplant] Abstract

Differential Effects of Mycophenolate Mofetil and Cyclosporine A on Peripheral Blood and Cord Blood Natural Killer Cells Activated with Interleukin-2
Investigators examined if the sensitivity of umbilical cord blood natural killer cells to mycophenolate mofetil and/or cyclosporine differs from their adult counterparts. [Cytotherapy] Abstract

Performance Evaluation of Sysmex XN Hematology Analyzer in Umbilical Cord Blood: A Comparison Study with Sysmex XE-2100
The Sysmex XN modular system is a new automated hematology analyzer equipped with different principles from its previous version, Sysmex XE-2100. Researchers compared the performances of Sysmex XN and XE-2100 in umbilical cord blood specimens. [Clin Chem Lab Med] Abstract

Comprehensive Characterization of Four Different Populations of Human Mesenchymal Stem Cells as Regards Their Immune Properties, Proliferation and Differentiation
Scientists compared mesenchymal stem cells (MSCs) derived from four different sources, human bone marrow, adipose tissue, umbilical cord Wharton’s Jelly and the placenta, in order to determine which population of MSCs displayed the most prominent immunosuppressive effects on phytohemagglutinin-induced T cell proliferation, and which one had the highest proliferative and differentiation potential. [Int J Mol Med]
Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Jazz Pharmaceuticals Announces Agreement to Acquire Rights to Defibrotide in the Americas from Sigma-Tau Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. under which a subsidiary of Jazz will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Defibrotide is a novel product that is marketed by Jazz in the European Union under the name Defitelio^® for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing hematopoietic stem cell transplantation therapy. [Jazz Pharmaceuticals plc] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Grant Writer – Pediatric Hematology, Oncology, Stem Cell Transplant, and Cancer Biology (Stanford University School of Medicine)

Cord Tissue Processing Technician (Cord Blood Registry)

Clinical HSCT Faculty Position (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Postdoctoral Researcher – Novel PSC-Based Blood Therapeutics (Fred Hutchinson Cancer Research Center)

Research Associate – Hematology/Oncology (University of Chicago)

Postdoctoral Researcher – Hematopoietic Stem Cells & iPSCs (KU Leuven)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.